title: Maintenance in CLL.
abstract: In this issue of Blood, Abrisqueta and colleagues report on the outcomes of a phase 2 clinical trial evaluating rituximab maintenance therapy in chronic lymphocytic leukemia (CLL) patients after treatment with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM).
authors: MEDICAL UNIVERSITY OF LODZ.
authors: Tadeusz
authors: T
authors: Robak
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D008297:Male